Item 2.02. Results of Operations and Financial Condition.

On January 24, 2022, Arbutus Biopharma Corporation (the "Company") issued a press release (the "Press Release") announcing its 2022 corporate objectives and providing certain estimated and projected financial information, including its estimated cash, cash equivalents and investments as of December 31, 2021. The amounts included in the Press Release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2021. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2021. A copy of the Press Release is furnished as Exhibit 99.1 hereto.

On January 24, 2022, the Company posted an updated corporate presentation on its website at www.arbutusbio.com (the "Corporate Presentation"), which included the Company's estimated cash, cash equivalents and investments as of December 31, 2021. A copy of the Corporate Presentation is furnished as Exhibit 99.2 hereto.

Item 8.01. Other Events.

On January 24, 2022, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 hereto and is incorporated by reference herein.

A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

Exhibit Number    Description

  99.1              Press Release dated January 24, 2022
  99.2              Corporate Presentation January 24, 2022
104               Cover Page Interactive Data File (embedded within the Inline
                  XBRL document)

© Edgar Online, source Glimpses